The evolving landscape of stage III unresectable non-small cell lung cancer "between lights and shadows"

被引：0

作者：

Delcuratolo, Marco Donatello ^{[1
,5
]}

Crespi, Veronica ^{[2
,5
]}

Saba, Giorgio ^{[3
,4
,5
]}

Mogavero, Andrea ^{[5
]}

Napoli, Valerio Maria ^{[5
]}

Garbo, Edoardo ^{[5
]}

Cani, Massimiliano ^{[5
]}

Ungaro, Antonio ^{[6
]}

Reale, Maria Lucia ^{[7
]}

Merlini, Alessandra ^{[5
]}

Capelletto, Enrica ^{[5
]}

Bironzo, Paolo ^{[5
]}

Levis, Mario ^{[8
]}

Ricardi, Umberto ^{[8
]}

Novello, Silvia ^{[5
]}

Passiglia, Francesco ^{[5
]}

机构：

[1] Fdn IRCCS, Med Oncol Unit, Casa Sollievo Sofferenza, San Giovanni Rotondo, FG, Italy

[2] Asst Sette Laghi, Dept Med Oncol, Varese, Italy

[3] Univ Hosp, Med Oncol Unit, I-09042 Cagliari, Italy

[4] Univ Cagliari, I-09042 Cagliari, Italy

[5] Univ Turin, Dept Oncol, AOU S Luigi Gonzaga, Orbassano, TO, Italy

[6] San Giuseppe Moscati Hosp, Med Oncol Unit, Statte, TA, Italy

[7] Vito Fazzi Hosp, Med Oncol Unit, Lecce, Italy

[8] Univ Turin, Dept Oncol, Radiat Oncol Unit, AOU Citta Salute & Sci, Turin, Italy

来源：

CANCER TREATMENT REVIEWS | 2025年 / 135卷

关键词：

stage III; Locally advanced; Unresectable; Immunotherapy; Non-small cell lung cancer; WORLD TREATMENT PATTERNS; CIRCULATING TUMOR DNA; REAL-WORLD; CONCURRENT CHEMORADIOTHERAPY; CLINICAL-OUTCOMES; PHASE-III; PLUS CHEMOTHERAPY; PROGRESSION-FREE; DURVALUMAB; NSCLC;

D O I：

10.1016/j.ctrv.2025.102918

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite PACIFIC set a new milestone in the clinical management of unresectable stage III non-small cell lung cancer (NSCLC), it left some critical questions pending for clinical research: the efficacy of durvalumab in the real-world setting; the activity of less intensive regimens for frail populations; the role of targeted therapies in oncogene-addicted tumors; the selection of subsequent strategies at immunotherapy failure; the efficacy of novel and intensified treatments; the role of molecular biomarkers for patients' selection. This review aims to describe the evolving landscape of unresectable stage III NSCLC and provides an updated overview of the available evidence, analyzing lights and shadows emerging from recent clinical trials and discussing the most relevant challenges of post-PACIFIC era.

引用

页数：11

共 104 条

[1] Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone
Abe, Takanori
Saito, Satoshi
Iino, Misaki
Aoshika, Tomomi
Ryuno, Yasuhiro
Ohta, Tomohiro
Igari, Mitsunobu
Hirai, Ryuta
Kumazaki, Yu
Miura, Yu
Kaira, Kyoichi
Kagamu, Hiroshi
Noda, Shin-ei
Kato, Shingo
[J]. THORACIC CANCER, 2021, 12 (02) : 245 - 250
[2] Aggarwal C, 2024, J CLIN ONCOL, V42
[3] Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer (vol 11, e007618, 2023)
Alessi, J., V
Price, A.
Richards, A. L.
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (01)
[4] Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
Alessi, Joao V. V.
Ricciuti, Biagio
Wang, Xinan
Pecci, Federica
Di Federico, Alessandro
Lamberti, Giuseppe
Elkrief, Arielle
Rodig, Scott J. J.
Lebow, Emily S. S.
Eicholz, Jordan E. E.
Thor, Maria
Rimner, Andreas
Schoenfeld, Adam J. J.
Chaft, Jamie E. E.
Johnson, Bruce E. E.
Gomez, Daniel R. R.
Awad, Mark M. M.
Shaverdian, Narek
[J]. NATURE COMMUNICATIONS, 2023, 14 (01)
[5] [Anonymous], ESMO IMM ONC C 2024
[6] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J.
Villegas, A.
Daniel, D.
Vicente, D.
Murakami, S.
Hui, R.
Kurata, T.
Chiappori, A.
Lee, K. H.
de Wit, M.
Cho, B. C.
Bourhaba, M.
Quantin, X.
Tokito, T.
Mekhail, T.
Planchard, D.
Kim, Y. -C.
Karapetis, C. S.
Hiret, S.
Ostoros, G.
Kubota, K.
Gray, J. E.
Paz-Ares, L.
Carpeno, J. de Castro
Faivre-Finn, C.
Reck, M.
Vansteenkiste, J.
Spigel, D. R.
Wadsworth, C.
Melillo, G.
Taboada, M.
Dennis, P. A.
Ozguroglu, M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) : 2342 - 2350
[7] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Antonia, S. J.
Villegas, A.
Daniel, D.
Vicente, D.
Murakami, S.
Hui, R.
Yokoi, T.
Chiappori, A.
Lee, K. H.
de Wit, M.
Cho, B. C.
Bourhaba, M.
Quantin, X.
Tokito, T.
Mekhail, T.
Planchard, D.
Kim, Y. -C.
Karapetis, C. S.
Hiret, S.
Ostoros, G.
Kubota, K.
Gray, J. E.
Paz-Ares, L.
de Castro Carpeno, J.
Wadsworth, C.
Melillo, G.
Jiang, H.
Huang, Y.
Dennis, P. A.
Ozguroglu, M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1919 - 1929
[8] Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
Aredo, Jacqueline V.
Mambetsariev, Isa
Hellyer, Jessica A.
Amini, Arya
Neal, Joel W.
Padda, Sukhmani K.
McCoach, Caroline E.
Riess, Jonathan W.
Cabebe, Elwyn C.
Naidoo, Jarushka
Abuali, Tariq
Salgia, Ravi
Loo Jr, Billy W.
Diehn, Maximilian
Han, Summer S.
Wakelee, Heather A.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) : 1030 - 1041
[9] Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC):: A meta-analysis of individual data from 1764 patients
Aupérin, A
Le Péchoux, C
Pignon, JP
Koning, C
Jeremic, B
Clamon, G
Einhorn, L
Ball, D
Trovo, MG
Groen, HJM
Bonner, JA
Le Chevalier, T
Arriagada, R
[J]. ANNALS OF ONCOLOGY, 2006, 17 (03) : 473 - 483
[10] Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer
Auperin, Anne
Le Pechoux, Cecile
Rolland, Estelle
Curran, Walter J.
Furuse, Kiyoyuki
Fournel, Pierre
Belderbos, Jose
Clamon, Gerald
Ulutin, Hakki Cuneyt
Paulus, Rebecca
Yamanaka, Takeharu
Bozonnat, Marie-Cecile
Uitterhoeve, Apollonia
Wang, Xiaofei
Stewart, Lesley
Arriagada, Rodrigo
Burdett, Sarah
Pignon, Jean-Pierre
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2181 - 2190

← 1 2 3 4 5 6 7 8 9 10 →